BusinessBeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLLBy Nasdaq OMXMar 9, 2017, 9:15 PM UTC
BusinessBeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111By Nasdaq OMXMar 2, 2017, 2:01 PM UTC
BusinessBeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s MacroglobulinemiaBy Nasdaq OMXJan 25, 2017, 1:01 PM UTC
BusinessBeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s MacroglobulinemiaBy Nasdaq OMXJan 25, 2017, 1:01 PM UTC
BusinessBeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 2016 American Society of Hematology Annual MeetingBy Nasdaq OMXDec 6, 2016, 3:00 AM UTC
BusinessBeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual MeetingBy Nasdaq OMXDec 5, 2016, 4:15 PM UTC
BusinessBeiGene Announces Oral Presentations on BTK Inhibitor BGB-3111 at the 2016 American Society of Hematology Annual MeetingBy Nasdaq OMXNov 3, 2016, 1:01 PM UTC
BusinessBeiGene Announces Oral Presentations on BTK Inhibitor BGB-3111 at the 2016 American Society of Hematology Annual MeetingBy Nasdaq OMXNov 3, 2016, 1:01 PM UTC
